Cholinesterase inhibitors such as rivastigmine may increase gastric acid secretion. Monitor closely for
manifestations of active or occult GI bleeding, especially in patients at increased risk (e.g., history of ulcer diseases, concomitant nonsteroidal anti-inflammatory agent therapy).